Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ChromaDex Corporation CDXC
$1.47
-$0.04 (-2.65%)
На 18:00, 12 мая 2023
+274.15%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
114522336.00000000
-
week52high
2.37
-
week52low
1.15
-
Revenue
72050000
-
P/E TTM
-8
-
Beta
1.79273300
-
EPS
-0.25000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 29 авг 2022 г. |
| Oppenheimer | Perform | Outperform | 16 авг 2022 г. |
| B. Riley Securities | Neutral | Buy | 11 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 07 июн 2022 г. |
| B. Riley Securities | Buy | Buy | 13 мая 2022 г. |
| HC Wainwright & Co. | Buy | 01 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Fried Robert N | A | 972314 | 80000 | 30 сент 2022 г. |
| Chau Hoi Shuen Solina Holly | A | 7885641 | 960000 | 30 сент 2022 г. |
| FARR KEVIN M | A | 89189 | 89189 | 12 авг 2022 г. |
| Gerber Brianna | A | 67308 | 67308 | 12 авг 2022 г. |
| Gerber Brianna | A | 100460 | 100460 | 12 авг 2022 г. |
| Shahbazi Hamed | A | 40000 | 40000 | 09 авг 2022 г. |
| YU Wing Tak Wendy | A | 20000 | 20000 | 16 июн 2022 г. |
| Rubin Steven D | A | 20000 | 20000 | 16 июн 2022 г. |
| Cohen Ann | A | 20000 | 20000 | 16 июн 2022 г. |
| Ng Wang Yu Gary | A | 20000 | 20000 | 16 июн 2022 г. |
Новостная лента
ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
Business Wire
11 мая 2023 г. в 08:34
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2023 Investor Conference. Mr. Fried and Mrs. Gerber will be participating in virtual one-on-one meetings throughout the event on Thursday, May 18, 2023. To arrange a meeting with the ChromaDex management team, please contact.
ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
10 мая 2023 г. в 18:59
ChromaDex (CDXC) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.11 per share a year ago.
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
Business Wire
02 мая 2023 г. в 08:32
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Q1Earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex manage.
ChromaDex Corporation (CDXC) Q4 2022 Earnings Call Transcript
Seeking Alpha
08 мар 2023 г. в 21:42
ChromaDex Corporation (NASDAQ:CDXC ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Tom Shumaker – LifeSci Advisors, Agency IR Counsel Rob Fried – Chief Executive Officer Brianna Gerber – Chief Financial Officer Andrew Shao – Senior Vice President-Scientific and Regulatory Affairs Conference Call Participants Mitch Pinheiro – Sturdivant Jeff Van Sinderen – B. Riley Ram Selvaraju – H.C.
ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
08 мар 2023 г. в 19:33
ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 0.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?